Cinepazide Maleate Research Articles

Sustainable and efficient separation of ternary multi-azeotropic mixture butanone/ethanol/water based on the intensified reactive extractive distillation: process design, multi-objective optimization, and multi-criteria decision-making

It is of great significance and necessity to develop a sustainable and efficient separation scheme of butanone (MEK), ethanol (EtOH), and water, which are usually formed during the cinepazide maleate synthesis process. To the best of our knowledge, the systematic separation of this ternary multi-azeotropic mixture remains comparatively less studied, compounded by the significant challenges posed by its intricate composition comprising four azeotropes and three distillation boundaries. Therefore, a systematic approach by integrating the process design, multi-objective optimization, and multi-criteria decision-making (MCDM) methods was proposed to achieve the sustainable separation. Initially, three separation schemes, i.e., triple-column extractive distillation (TCED), double-column reactive extractive distillation (DCRED), and side stream intensified double-column reactive extractive distillation (SS-DCRED), were mainly explored via the thermodynamic and kinetic analysis. Subsequently, the multi-objective particle swarm optimization (MOPSO) algorithm was employed to optimize the process based on three objectives namely the total annual cost (TAC), CO2 emissions, and process route index (PRI). Finally, an efficient MCDM method combining CRITIC and TOPSIS was employed to rank the Pareto front solutions of the corresponding process design. Based on the comparison results, the optimal TCED process exhibits the lowest PRI with a decrease of 50.61% and 55.06% compared to that of the SS-DCRED and the DCRED, respectively. It also shows the best performance simultaneously considering economic, environmental, and safety criteria. Of note, the SS-DCRED separation process exhibited the lowest TAC, with a decrease of 60.67% and 11.45% compared to that of the TCED and the DCRED, respectively.

Cinepazide maleate promotes recovery from spinal cord injury by inhibiting inflammation and prolonging neuronal survival.

This study aimed to investigate the therapeutic effects of cinepazide maleate (CM) on spinal cord injury (SCI) in rats, thereby providing an experimental basis for the use of CM as a preventative and therapeutic strategy for SCI. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining and western blot analysis were used to assess neural cell apoptosis. enzyme-linked immunosorbent assay was used to analyze the expression of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) in spinal cord tissues and cerebrospinal fluid. CD68 staining and western blot analysis were used to investigate the effect of CM on microglia activation. The effects of CM on motor function and histological damage in rats after SCI were investigated using the Basso-Beattie-Bresnahan (BBB) score, footprint assay, hematoxylin and eosin staining, and NeuN staining. In vitro models of neuronal cell injury and microglial inflammation were developed to investigate the effects of CM on apoptosis and inflammation. Functional tests (BBB score and footprint test) revealed that CM-treated rats had significantly improved motor function. In vivo CM treatment reduced the number of apoptotic cells at the site of injury. Similarly, in vitro CM treatment reduced H2 O2 -induced neuronal apoptosis. In vivo CM treatment reduced the number of CD68-positive microglia and the expression levels of TNF-α, IL-1β, and IL-6. Similarly, in vitro CM treatment reduced LPS-induced pro-inflammatory cytokines in microglia. CM promotes the recovery of motor function by inhibiting SCI-induced apoptosis and inflammatory responses and reducing the area of the post-SCI cavity in rats. These findings indicate that CM is a potential drug worthy of translational studies for SCI treatment.

Effects of cinepazide maleate injection on blood pressure in patients with acute ischemic stroke and hypertension

Objective: To investigate the blood pressure change in patients with acute ischemic stroke (AIS) and hypertension treated with cinepazide maleate injection. Methods: This was a subgroup analysis of post-marketing clinical confirmation study of cinepazide maleate injection for acute ischemic stroke: a randomized, double-blinded, multicenter, placebo-parallel controlled trial, which conducted in China from August 2016 to February 2019. Eligible patients fulfilled the inclusive criteria of acute anterior circulation ischemic stroke with National Institutes of Health Stroke Scale (NIHSS) scores of 7-25. The primary endpoints were mean blood pressure of AIS patients treated with cinepazide maleate or control, which were assessed during the treatment period (14 days), and the proportion of the patients with normal blood pressure was analyzed after the treatment period. Furthermore, a subgroup analysis was performed to investigate a possible effect of the history of hypertension on outcomes. Results: This analysis included 809 patients with hypertension. There was no significant difference in patients blood pressure and the proportion of patients with normal blood pressure (60.5% vs. 59.0%,P>0.05) between cinepazide maleate group and control group. Conclusion: Administration of cinepazide maleate injection does not affect the management of clinical blood pressure in patients with AIS.

Effect of Cinepazide Maleate on Serum Inflammatory Factors of ICU Patients with Severe Cerebral Hemorrhage after Surgery.

Objective To explore the effect of cinepazide maleate on serum inflammatory factors of intensive care unit (ICU) patients with severe cerebral hemorrhage after surgery. Methods 116 ICU patients with severe cerebral hemorrhage treated in Taian Maternal and Child Health Hospital from June 2018 to June 2020 were selected as the research objects and randomly divided into the control group and experimental group, with 58 patients in each group. The control group was given routine treatment, while the experimental group was additionally given an intravenous drip of cinepazide maleate to compare the clinical efficacy and serum inflammatory factors between the two groups. Results The total effective rate in the experimental group was higher than that in the control group (P < 0.05). After treatment, the Glasgow Coma Scale (GCS), National Institutes of Health Stroke Scale (NIHSS), and Fugl-Meyer scores in both groups were better than those before treatment, and the scores in the experimental group were better than those in the control group (P < 0.05). The oxidative stress indexes such as total antioxidant capacity (T-Aoc), superoxide dismutase (SOD), and glutathione peroxidase (GSH-PX) in the experimental group were higher than those in the control group, while malondialdehyde (MDA) in the experimental group was lower than that in the control group (P < 0.05). The high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α) levels in the experimental group were lower than those in the control group (P < 0.05). Compared with the control group, the cerebrovascular function in the experimental group was significantly improved (P < 0.05), with statistically significant differences. Conclusion Cinepazide maleate can effectively reduce the serum inflammatory factor levels of ICU patients with severe cerebral hemorrhage after surgery, alleviate the oxidative stress response in the body, and improve the cerebrovascular function and cerebral nerve function, which is worthy of clinical promotion.

Effect of Cinepazide Maleate Combined with Promethazine Hydrochloride in the Treatment of Emergency Vertigo

Objective: To explore the effect of cinepazide maleate combined with promethazine hydrochloride in the treatment of emergency vertigo. Methods: 48 cases of emergency vertigo patients in our hospital from November 2017 to November 2019 were divided into experimental group (24 cases, treated with cinepazide maleate combined with promethazine hydrochloride) and control group (24 cases, treated with cinepazide maleate). The clinical efficacy, symptom relief time, adverse reactions and quality of life were compared. Results: The total effective rate of the experimental group (95.83%, 23 / 24) was higher than that of the control group (75.00%), The remission time of nausea and vomiting (1.75 ± 0.22) d, vertigo (3.54 ± 0.63) d, deafness and tinnitus (3.47 ± 0.58) d, night sweats (3.05 ± 0.33) d in the experimental group were shorter than those in the control group, P &lt; 0.05; the incidence of adverse reactions in the experimental group (8.33%, 2 / 24) was lower than that in the control group (33.33%, The scores of social function, material life attitude, physical health and psychological function in the experimental group were 59.14 ± 7.23, 54.05 ± 8.04, 53.58 ± 8.86 and 60.11 ± 8.44 respectively, P &lt; 0.05. Conclusion: In the process of clinical treatment of emergency vertigo patients, the combined application of cinepazide maleate and promethazine hydrochloride has definite curative effect, can relieve clinical symptoms in a short time, has less adverse reactions, and improves the quality of life of patients to a certain extent, which is worthy of promotion.

Effectiveness of Chinese herbal medicine for primary Raynaud's phenomenon: a systematic review and Meta-analysis of randomized controlled trials.

To evaluate the effectiveness of Chinese herbal medicine for primary Raynaud's phenomenon (PRP). The Cochrane Central Register of Controlled Trials, PubMed, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Wanfang Database were searched up to February 13, 2018. Randomized controlled trials (RCTs) on treatment of PRP with Chinese herbal medicine compared with placebo, blank control, lifestyle changes, or calcium antagonists were identified and reviewed. The quality of included trials was assessed using a risk of bias tool. Eight RCTs involving 674 participants were included. The methodological quality of the included trials was generally poor. Meta-analysis of two trials showed that Buyang Huanwu Tang plus Danggui Sini Tang produced greater improvement in global symptoms than nifedipine. One trial showed that Danggui Sini Tang and a self-composed Chinese herbal medicine decoction, respectively, produced greater improvement in global symptoms than nifedipine alone. In one trial, modified Danggui Sini Tang showed greater improvement in global symptoms and arterial peak systolic velocity compared with nifedipine. One trial showed that Jiejing Tongmi Tang produced greater improvement in global symptoms, plasma endothelin, and plasma nitric oxide than cinepazide maleate injection. However, Jiejing Tongmi Tang did not produce a significant difference in skin temperature and peripheral artery blood stream drawing after cold pressor testing compared with cinepazide maleate injection. None of the trials reported frequency of attacks, duration of attacks, participant preference scores, or adverse events. Chinese herbal medicine may have a positive effective on PRP. However, owing to weak methodology, the benefits of Chinese herbal medicine for PRP are inconclusive. More rigorously designed studies are needed to confirm these findings.

Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial

BackgroundIschemic stroke is a leading cause of morbidity and mortality. Thrombolytic therapy improves disability and survival rates; however, to be effective, it must be given within 4.5 h of onset. Moreover, thrombolytic therapy is frequently contraindicated. Therefore, alternative therapeutic options are required. In China, cinepazide maleate injection has been shown to improve the cerebral collateral circulation and further reduce disability in stroke patients; however, very few studies investigating this therapy have been conducted to date. Therefore, this study aimed to further confirm the efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke.MethodsPatients with acute ischemic stroke were administered an intravenous infusion of 320 mg cinepazide maleate or placebo once daily for 14 days. All patients were also administered basic therapy (citicoline sodium). The primary efficacy endpoint was the proportion of patients with a modified Rankin scale (mRS) ≤2 on day 90. Secondary efficacy endpoints included Barthel Index ≥95. Safety was evaluated by recording all adverse events (AEs), monitoring laboratory parameters and vital signs, and electrocardiogram.ResultsIn total, 937 patients with an acute ischemic stroke were included, with a mean (standard deviation, SD) National Institutes of Health Stroke Scale score of 8.8 (2.4) and a mean (SD) stroke onset of 30.9 (11.4) hours prior. Following treatment for 90 days, the proportion of patients with an mRS score ≤ 2 was significantly higher in the cinepazide maleate group than in the control group (60.9% vs. 50.1%; p = 0.0004). Moreover, the proportion of patients with a Barthel Index of ≥95 on day 90 was also significantly higher in the cinepazide maleate group than in the control group (53.4% vs. 46.7%; p = 0.0230). There were no statistically significant differences in safety parameters between the cinepazide maleate and control groups.ConclusionsThe results of this study show that cinepazide maleate injection is superior to placebo in improving neurological function and activities of daily living, reducing disability, and promoting functional recovery in patients with acute ischemic stroke. Cinepazide maleate injection was safe and well tolerated with no unexpected AEs reported.Trial registrationChinese Clinical Trial Registry CTR20160292 and ChiCTR1900023827. Retrospectively registered June 13, 2019.

Influence of butyphthalide combined with urinary kallikrein in ACI treatment on neuro-cytokines and vascular endothelial function and its clinical effect

Objective: To study the influence of butyphthalide combined with urinary kallikrein in acute cerebral infarction (ACI) treatment on neuro-cytokines and indicators of vascular endothelial function, observe the curative effect and adverse effects, and discuss its safety and feasibility.Method: 110 ACI patients were chosen as the objects, and classified into observation group (55 cases) and control group (55 cases) according to the method of random number table. Butyphthalide injection combined with urinary kallikrein was adopted for the observation group based on conventional treatment, while cinepazide maleate injection combined with alprostadil injection was applied for the control group based on conventional treatment. The following indicators of both groups were compared before and after treatment: neurotrophic factor (NTF), nerve growth factor (NGF), neuron specific enolase (NSE); content of CXC chemotactic factor ligand 16 (CXCL16), soluble CD ligand (CD40L), Fibulin-5 and high mobility group box B1 (HMGB1); the content of indicators of vascular endothelial function including plasma endothelin −1 (ET-1) and no therapeutic effects and adverse effects were recorded.Results: NSE of both groups after treatment decreased obviously, and the content of NTF and NGF increased obviously. NSE content of observation group was lower than that of control group. NTF content and NGF content of observation group were higher than those of control group. The differences had statistical significance (p < 0.05). The levels of CXCL16, CD40L, Fibulin-5 and HMGB1 declined obviously, compared with pre-treatment, and the levels of observation groups were significantly lower than those of control grip. The differences had statistical significance (p < 0.05). ET-1 level rose significantly after treatment, and NO level declined obviously after treatment. ET-1 level of observation group was significantly higher than that of control group, and NO level of observation group was significantly lower than that of control group. The difference had statistical significance (p < 0.05). Clinical effect of observation group was significantly higher than that of control group. The difference had statistical significance (p < 0.05). The comparison difference of both groups in the occurrence rate of adverse effects had no statistical significance (p > 0.05).Conclusion: The application of butyphthalide combined with urinary kallikrein in ACI treatment can effectively inhibit secretion and release of neuro-cytokines, and improve patients’ vascular endothelial function, with significant treatment effect and high safety. Therefore, it deserves to be promoted clinically.

Edaravone combined with cinepazide maleate on neurocyte autophagy and neurological function in rats with subarachnoid hemorrhage.

Effects of edaravone combined with cinepazide maleate on neurocyte autophagy and neurological function in rats with subarachnoid hemorrhage were investigated. Eighty SD rats were selected to establish subarachnoid hemorrhage (SAH) rat models, which were divided into sham operation group, SAH group, MCI group and combined group. Hippocampal tissue of each group was taken to observe the number of neurocytes. The expression levels of Beclin-1 and (light chain LC3)-II of rats in each group were detected by ELISA. Pearson's correlation factors were used to analyze the correlation between Beclin-1 and LC3-11, and neurological function tests were carried out on rats of each group 14 and 28 days after administration. The morphological and structural damage of nerve cells in the combined group was further alleviated, and the survival rate of neurons significantly increased at all time points (P<0.05). The expression levels of Beclin-1 and LC3-11 in combined group was significantly higher than those in SAH group and CMI group (P<0.05), and Beclin-1 was positively correlated with LC3-11 (r=0.9454). Longa score of the combined group was significantly lower than that of the other two groups, and muscle strength score was significantly higher than that of the other two groups (P<0.05). Edaravone combined with cinepazide maleate can effectively increase the survival rate of brain cells and promote the volatilization of neurological function in the treatment of hemorrhage in the subretinal space of the omentum, which is worthy of popularization and application.

Neuroprotective strategies for patients with acute myocardial infarction combined with hypoxic ischemic encephalopathy in the ICU

BackgroundWe investigated neuroprotective treatment strategies for patients with acute myocardial infarction (AMI) complicated with hypoxic ischemic encephalopathy (HIE) in the ICU. MethodsThe 83 cases diagnosed with secondary AMI were, for the first time, divided into an observation group (n = 43) and control group (n = 40). All of the patients underwent emergency or elective PCI. Patients in the control group were treated with mannitol to reduce intracranial pressure and cinepazide maleate to improve microcirculation in the brain as well as given a comprehensive treatment with oxygen inhalation, fluid infusion, acid-base imbalance correction and electrolyte disturbance. Patients in the observation group underwent conventional treatment combined with neuroprotective therapeutic strategies. The effects of the different treatment strategies were compared. ResultsConsciousness recovery time, reflex recovery time, muscle tension recovery time and duration of ICU stay were significantly shorter in the observation group compared with the control group (P < 0.05). After treatment, the jugular vein oxygen saturation (SjvO2) and blood lactate (JB-LA) levels of both groups were lower than before treatment and the cerebral oxygen utilization rate (O2UC) increased, with a significantly higher increase in the observation group (P < 0.05). After treatment, the activities of daily living (ADL) score was higher for both groups and the neural function defect (NIHS) score was lower. ConclusionThe neuroprotective strategies of hypothermia and ganglioside administration assisted with hyperbaric oxygen was effective for treating AMI patients with HIE and may be worth clinical promotion.

Cinepazide Maleate Improves Cognitive Function and Protects Hippocampal Neurons in Diabetic Rats with Chronic Cerebral Hypoperfusion.

To determine the combined effect of type 2 diabetes (T2D) and chronic cerebral hypoperfusion (CCH) on learning and spatial memory, we developed a rat model of CCH by permanent occlusion of bilateral common carotid arteries (2-vessel occlusion (2VO)) in high-fat diet (HFD)-fed rats injected with low-dose streptozotocin (STZ). Furthermore, we examined the effect of cinepazide maleate (CM) on cognitive deficits and brain damage in this rat model. Rats were maintained on HFD for 6 weeks and then injected with 35 mg/kg STZ to induce T2D. Sham or 2VO surgery was performed in non-diabetic or diabetic (DM) rats to obtain four groups: blank, DM, CCH, and DM-CCH groups. Cognitive function was tested by the Morris water maze (MWM) test. To determine the effects of the vasodilator cinepazide maleate (CM) on cognitive deficits and brain damage, DM-CCH rats were administered with 10 mg/kg CM or saline daily for 14 d. Neuronal damage in DM-CCH rats was associated with increased expression of glial fibrillary acidic protein (GFAP) and β-secretase 1 (BACE1), but decreased expression of choline acetyltransferase (ChAT). Moreover, the levels of all these proteins were significantly alleviated by CM treatment. These results suggest that T2D exacerbated CCH-induced brain damage and cognitive impairment, and CM ameliorated these effects.

Analysis of Diemailing Kudiezi injection use in real world in 7 189 patients with cerebral infarction

This is a study based on hospital intensive monitoring to explore medication use of Diemailing Kudiezi injection(one Chinese herbal medicine injection) in real word in the patients with cerebral infarction. The active monitoring model was adopted and hospital intensive monitoring on safety of 7 189 cases of patients with cerebral infarction was conducted to obtain the drug use information of Diemailing injection. The results were analyzed by using statistical description and association rule method. The statistical description and association rule analysis were conducted based on patients' basic demographic characteristics, use of Diemailing injection and combined use of drugs. Sixty-two percent(4 437/7 189) of the patients were from traditional Chinese medicine hospitals as compared with 39%(2 752/7 189) from western medicine hospitals; 84%(6 003/7 189) of the patients were from tertiary hospitals as compared with 16%(1 186/7 189) from second-class hospitals. The hospitals were mostly located in north China. Drug related indicators such as a single dripping speed, stash time after allocating transfusion, duration of injection, and injecting room temperature were not noted in instruction manual. It was also found that there were off label use in the practice, for instance, non-intravenous infusion, >14 d treatment course, use of non-designated solvent, and a single dose>40 mL or<10 mL. Analysis of association rules showed that only Edaravone among the most frequent combined drugs was listed in the current guideline in China, and the other three most frequent combined drugs deproteinized calf blood extractive injection, Cinepazide Maleate injection and Alprostadil injection were used with little evidence. Diemailing＋Aspirin＋Alprostadil was the most common combined use in our study, but the recommended clopidogrel＋Aspirin was not found in this study. The drug use situation of Diemailing injection in the real world was obtained by data analysis on large size samples, providing basic reference information for clinicians and researchers. However, efficacy was not concerned in this study, so efficacy-related information could not be explained.

Observation of the effect of cinepazide maleate combined with Shuxuetong in the treatment of ischemic vertigo

Objective To learn the effect of cinepazide maleate combined with Shuxuetong in the treatment of ischemic vertigo. Methods 181 cases with ischemic vertigo were randomly divided into the observation group(98 cases) and the control group(83 cases) by random number table method.The observation group was treated with cinepazide maleate combined with Shuxuetong, and the control group was treated with cinepazide maleate.The blood flow velocity of vertebral artery and basilar artery of the two groups were measured before and after a period of treatment.The therapeutic effects were evaluated after one course. Results The peak systolic velocity and end diastolic velocity of right vertebral artery, left vertebral artery and basilar artery of the two groups were higher than before treatment, the differences were statistically significant(t=11.215, 12.510, 6.030, 6.814, 7.052, 7.730, 19.884, 17.774, 10.954, 19.320, 19.483, 19.198, all P 0.05). Conclusion In the treatment of ischemic vertigo, cinepazide maleate combined with Shuxuetong has better curative effect and low incidence rate of drug adverse reaction. Key words: Vertigo; Brain ischemia; Cinepazide maleate; Shuxuetong

Influence of Cinepazide Maleate on Vascular Endothelial Function of Patients with Acute Myocardial Infarction

&lt;strong&gt;Objective&lt;/strong&gt;: To study influence of cinepazide maleate on vascular endothelial function of patients with acute myocardial infarction. &lt;strong&gt;Methods&lt;/strong&gt;: 150 cases of patients with acute myocardial infarction were divided into the observation group and the control group, two groups were treated by conventional therapy about acute myocardial infarction, the observation group added 5%GS250 mL + cinepazide maleate 160 mg IV drip q.d, the control group added 5%GS250 mL IV drip q.d, the treatment course were 3 weeks, changes of vascular endothelial function and the blood serum no level before and after treatment were detected. &lt;strong&gt;Result&lt;/strong&gt;: vascular endothelial function after treatment in observation group were obviously improved than that before treatment (&lt;em&gt;p&lt;/em&gt; = 0.03) , blood serum no level was obviously increased (&lt;em&gt;p&lt;/em&gt; ﹤ 0.05); about 3 weeks after treatment, vascular endothelial function in the observation group was obviously better than that of the control group (&lt;em&gt;p&lt;/em&gt; = 0.04), the blood serum no level of the observation group was obviously higher than that of the control group (&lt;em&gt;p&lt;/em&gt; ﹤ 0.05).&lt;strong&gt; Conclusion&lt;/strong&gt;: Cinepazide maleate remarkably improves vascular endothelial function of patients with acute myocardial infarction.

The neuroprotection of cinepazide maleate on acute cerebral ischemic brain in rats: a proton magnetic spectroscopy study

Objective To dynamically monitor the effect of Cinepazide maleate (CM) on ischemic region of the brain and to elucidate the neuroprotection of CM on acute cerebral ischemic rat model and related mechanisms. Methods The rat model of acute brain ischemia-reperfusion was established with tighting threads. They were randomly divided into ischemia-reperfusion group and CM treatment group(n=8 in each group). Rats in CM treatment group were given 3 mg / kg CM by caudal intravenous injection immediately after brain ischemia-reperfusion. T2 weighted imaging(T2WI) and proton magnetic resonance spectroscopy (1HMRS) were performed before operation and at 6 hours, 24 hours and 3 days after reperfusion. Results At 6 h, 24 h and 3 d after operation there was no difference for areas of cerebral ischemia on T2WI between 2 groups. The values of N-acetylaspartate(NAA) (Phosphocreatine(PCr) + Creartine(Cr)) in ischemia-reperfusion group rats were (1.53±0.20), (0.50 ±0.17), (0.44±0.13), (0.40±0.10) before operation and at 6 h, 24 h, 3 d after operation, respectively. And in CM treatment group the values of NAA /(PCr+ Cr) were (1.44±0.22), (0.68±0.13), (0.61±0.10), (0.53±0.09) at the same time points. The values of lactate(Lac)/(PCr+ Cr) in ischemia-reperfusion group were (0.03±0.01), (1.10±0.28), (1.30±0.23), (1.23±0.19) before operation and at 6 h, 24 h, 3 d after operation, respectively. And in CM treatment group the values of Lac/(PCr+ Cr) were (0.02±0.01), (0.85±0.25), (0.99±0.20), (0.90±0.15 )at the same time points. The rats in ischemia-reperfusion group had lower value of NAA/(PCr+ Cr)(P<0.01) and higher value of Lac/(PCr+ Cr) at all time points after operation than those before operation. Compared with rats in ischemia-reperfusion group, the value of NAA/(PCr+ Cr) increased(P<0.05) and the value of Lac/(PCr+ Cr) decreased(P<0.05)decreased significantly for CM treatment group rats. Conclusion CM treatment can decrease the intracellular accumulation of lactic acid and reduce neuronal necrosis in acute brain ischemia-reperfusion rats. Key words: Magnetic resonance spectroscopy; Cinepazide maleate; Cerebral ischemia

Analysis of clinical use of Shuxuening injection in treatment of cerebral infarction based on real world

To know the characteristics of Shuxuening injection used on cerebral infarction patients in clinical practice, 6 053 cases of Hospital information system (HIS) data from 20 hospitals were analyzed. Using the basic description method and association rules to analysis the data. By analysis the data we found that the average age of cerebral infarction patients who used Shuxuening injection is 67.96, 83.94% of patients were aged 46-80. The injection is administered intravenously,with most patients receiving a dosage of 15-20 mL per dose for between 1 and 14 days. It is always combined with aspirin (48.508%), cinepazide maleate injection (22.073%), atorvastatin calcium tablets (18.873%) in clinical practice. When it comes to two drug combinations, it always combined with cinepazide maleate injection and aspirin (8.178%), nicergoline capsules and aspirin (7.63%). Therefore, based on existing data, we give the conclusion that for the treatment of cerebral infarction Shuxuening injection is mainly used for older patients, and is often combination with similar pharmacological effects chemical drugs, which is complied with the guidelines. However, the wrong dose is still exist, doctors should realize the hiding risk.

High performance liquid chromatographic method for the determination of cinepazide maleate and its application to a pharmacokinetic study in rats

A simple and reliable high performance liquid chromatographic (HPLC) method has been developed and validated to quantify cinepazide maleate, a calcium blocker, in rat plasma. Cinepazide maleate and Tinidazole (internal standard) have been extracted by a simple liquid-liquid extraction before injection into chromatographic system. Chromatographic separation was achieved on a reversed phase C18 column with a mobile phase consisted of a water mixture of 10mM potassium dihydrogen phosphate (pH=4.5):methanol (40:60, v/v), pumped at flow rate of 1.0mL/min, and detected at 303nm. The method exhibited a linear range of 0.12-120μg/mL in blank rat plasma, with the lower detection limit of 0.06μg/mL. The method was statistically validated for linearity, accuracy, precision, selectivity and stability following FDA guidelines. The intra- and inter-assay coefficients of variation did not exceed ±15% from the nominal concentration. The accuracy of cinepazide maleate was within ±15% of the theoretical value. The assay has been applied successfully in a pharmacokinetic study of cinepazide maleate after a single intravenous at three doses in rat. And cinepazide maleate injection can improve the bioavailability of cinepazide maleate greatly, and has a dose-dependence profile in rats.

Cinepazide maleate protects PC12 cells against oxygen–glucose deprivation-induced injury

Our previous study showed that cinepazide maleate (CM) was as effective and safe as mildronate in the treatment of acute ischemic stroke in a randomized, double-blind, active-controlled phase II multicenter trial, but underlying mechanism(s) is not well understood. As an extending study, here we demonstrated that CM could protect neuronal cells by affecting mitochondrial functions. PC12 cells were exposed to 2.5 h oxygen-glucose deprivation (OGD) followed by a 24 h reoxygenation, and then treated with different concentrations (1, 10, 100 μM) of CM. Among various concentrations, 10 μM CM exhibited most significant protection on PC12 cells against OGD injury. CM was found to suppress OGD-induced oxidative stress, as supported by its capability of reducing intracellular reactive oxygen species and malondialdehyde production and enhancing superoxide dismutase activity. Importantly, our results showed that CM could preserve mitochondrial functions, as revealed by its capability of stabilizing mitochondrial membrane potential, improving OGD-induced suppression of mitochondrial respiratory complex activities and enhancing ATP production. In summary, our present study provides the first evidence that CM can protect neuronal cells against OGD injury by preserving mitochondrial functions.

Comparison of adverse effect between Cinepazide Maleate and low Molecular Dextran injection after digital replantation surgery

Objective Comparing the clinical effect between Cinepazide Maleate and low Molecular weight Dextran,to the one which is more effective,safer and less unhealthy to patients after digital replantation.Methods From April 2010 to April 2012 in our hospital during single finger replantation patients,the observation group 120 cases of postoperative to Cinepazide Maleate injection 320mg/d intravenous drip,the control group of 120 cases treated with low Molecular Dextran 500ml/d IVGTT.Results The effective rate of observe group and control group was 96.67％ and 92.50％,respectively.The difference between the two groups was too small to have statistically significant difference (P ＞ 0.05),but the adverse effect of treatment group was only 5.8％,much lower than 14.17％ in control group however with the statistically significant difference (P ＜0.05).Conclusion Cinepazide Maleate Injection and low Molecular weight Dextran both have apparent effect in patients after digital replantation surgery.Both of them significantly improved microcirculation,enhanced the survival rate of replantation.However Cinepazide Maleate injection has fewer adverse effects,which is one of idea auxiliary medicine and deserved more extensive clinic application in currently microsurgery. Key words: Cinepazide Maleate injection; Low molecular weight dextran; Digital replantation; Adverse effect

Analysis on the therapeutic effects of cinepazide maleate in treatment for the patients with acute aggravation of chronic pulmonary heart disease

Objective To observe the therapeutic effects of cinepazide maleate in treatment for the patients with acute aggravation of chronic pulmonary heart disease(CPHD).Methods 60 patients with acute aggravation of CPHD from our hospital were randomly divided into control group and treatment group,30 patients for each group.Conventional treatment was given in the control group,while cinepazide maleate(320 mg/d)was used in the treatment group on the basis of conventional treatment,7 days as one period of treatment.The treatment efficiency,the level of blood brain natriuretic peptide(BNP)and D-dimer(D-D)were observed.Results The clinical total effective rate of the treatment group was 93.3％,significantly higher than that of the control group(73.3％)(P＜ 0.01),the level of blood BNP and D-D decreased significantly(P＜ 0.05)in both treatment group and control group,the difference was statistically significant(P ＜ 0.05).Conclusion Cinepazide maleate can increase the treatment efficiency,reduce the blood viscosity and improve heart failure to patients with acute aggravation of CPHD. Key words: Cinepazide maleate; Chronic pulmonary heart disease(CPHD)